Fulvestrant Injection
Product Images NDC 68462-317

18 FDA label images from Glenmark Pharmaceuticals Inc., Usa · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Fulvestrant (NDC 68462-317). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Ctn

Ctn
Packaging label for Fulvestrant Injection 250 mg/5 mL (50 mg/mL) by Glenmark Pharmaceuticals Inc., USA. The carton is marked Rx only and states that it contains 2 single-dose pre-filled syringes. The label includes dosage form (injection), route of administration (intramuscular), and handling instructions with illustrations.*
FDA Label Image

Figure1

Figure1
An instructional diagram showing the preparation steps for an injection. It depicts a hand holding a syringe with a twist arrow indicating rotation, a separate needle cap labeled with arrows A, B, and C, which likely correspond to specific components or actions involved in using the injection device.*
FDA Label Image

Figure10

Figure10
A Kaplan-Meier survival curve chart showing overall survival probability (%) over time in months. Two treatment groups are compared: Fulvestrant plus palbociclib (solid line) and Fulvestrant plus placebo (dashed line). The chart includes patient numbers at risk in each group at various time points up to 48 months.*
FDA Label Image

Figure11

Figure11
A Kaplan-Meier survival curve graph showing progression-free survival probability (%) over time (months) comparing Fulvestrant plus Abemaciclib versus Fulvestrant plus Placebo. The solid line represents Fulvestrant plus Abemaciclib, and the dashed line represents Fulvestrant plus Placebo, with censored observations marked. Patient counts at risk at various time points are shown below the graph.*
FDA Label Image

Figure12

Figure12
Kaplan-Meier survival curve graph showing survival probability (%) over time in months for patients treated with Fulvestrant injection plus Abemaciclib versus Fulvestrant plus placebo. The graph includes censored observations and patient counts at risk for both treatment groups over a 57-month period.*
FDA Label Image

Figure13

Figure13
A Kaplan-Meier survival curve illustrating event-free probability over time (months) for patients treated with Fulvestrant plus Ribociclib and Fulvestrant plus Placebo. The chart shows the proportion of patients event-free from 0 to 26 months, with a table indicating the number of patients still at risk at various time points for each treatment group.*
FDA Label Image

Figure14

Figure14
A Kaplan-Meier survival curve showing event-free probability over time (in months) for two treatment groups: Fulvestrant plus Ribociclib (N=484) and Fulvestrant plus Placebo (N=242). The chart includes censoring times and a table of patients at risk at various time points up to 48 months.*
FDA Label Image

Figure9

Figure9
A Kaplan-Meier survival curve chart showing progression-free survival probability (%) over time in months for patients treated with Fulvestrant plus palbociclib versus Fulvestrant plus placebo. The graph includes lines for both treatment groups and numbers of patients at risk at various time points.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
An instructional diagram showing the steps to remove a cap from a vial. The illustration highlights twisting the cap (labeled A), pulling it off (B), and exposing the vial opening (C). This visual guide aids in preparing the Fulvestrant injection for intramuscular use.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
Illustration showing a pair of gloved hands preparing a syringe, likely drawing fluid from a vial or cartridge, relevant to the administration of an injectable medication such as Fulvestrant injection.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
An illustration showing a step in the preparation or administration of an injection, featuring a syringe with a plunger and a vial with a partially removed cap. The image likely demonstrates a method related to the Fulvestrant 50 mg/mL intramuscular injection.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
An instructional illustration showing a hand holding an injection syringe with an arrow indicating the direction to pull back the plunger. This diagram is related to the administration of Fulvestrant injection (50 mg/mL) by intramuscular route.*
FDA Label Image

Figure-6 (Figure 6)

Figure-6 (Figure 6)
Kaplan-Meier curve chart showing progression free survival over time (months) for Fulvestrant 250 mg and 500 mg doses in an ITT population. The Y-axis measures the proportion of patients progression free, and the X-axis shows time up to 45 months. Patient numbers at risk at various time points are listed for each dose group below the graph.*
FDA Label Image

Figure-8 (Figure 8)

Figure-8 (Figure 8)
A Kaplan-Meier survival plot comparing two treatments over time from randomization in hours. The graph shows probability on the y-axis and time on the x-axis, with two curves representing Fulvestrant 500 mg and Anastrozole 1 mg treatment groups. A number-at-risk table is presented below the graph, showing patient counts for each group at various time points.*
FDA Label Image

Figure7 (Figure7)

Figure7 (Figure7)
A Kaplan-Meier survival curve graph showing the proportion of patients alive over time (months) for Fulvestrant at two doses, 500 mg and 250 mg. The x-axis represents time in months up to 80, and the y-axis shows the proportion of patients alive from 0.0 to 1.0. The graph includes tick marks indicating censored observations and a table listing the number of patients at risk at various time points for each dose group.*
FDA Label Image

Image 01

Image 01
FDA Label Image
Logo (Logo)
FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure of fulvestrant, showing its steroidal backbone with hydroxyl groups and a sulfonyl-containing side chain, including fluorine substituents.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.